Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 20/20 | 0.86 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922061 | 0.93 | OPRD1 (1.00) | OPRD1OPRK1OPRM1 | |
| SCHEMBL27531265 | 0.83 | OPRD1 (0.61) | OPRD1OPRK1OPRM1 | |
| SCHEMBL4914490 | 0.80 | OPRD1 (1.00) | OPRD1OPRK1OPRM1 | |
| SCHEMBL4921546 | 0.79 | OPRD1 (1.00) | OPRD1OPRK1OPRM1 | |
| SCHEMBL4923260 | 0.77 | OPRD1 (1.00) | OPRD1OPRK1OPRM1 | |
| SCHEMBL14173646 | 0.75 | OPRD1 (0.87) | OPRD1OPRK1OPRM1 | |
| SCHEMBL4922319 | 0.75 | OPRD1 (1.00) | OPRD1OPRK1OPRM1 | |
| SCHEMBL21581202 | 0.73 | OPRD1 (0.63) | OPRD1OPRK1OPRM1 | |
| SCHEMBL4912109 | 0.72 | OPRD1 (1.00) | OPRD1OPRK1OPRM1 | |
| SCHEMBL27533598 | 0.71 | OPRD1 (0.62) | OPRD1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390822-B2 | Substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | claimed |
| CN-100354273-C | Substituted 4-phenyl-4- (1H-imidazol-2-yl) -piperidine derivatives and their use as selective non-peptide delta opioid agonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-12 | — | — | CN | claimed |
| US-7282508-B2 | Substituted 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives and their use as selective non-peptide delta opioid agonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-16 | — | — | US | claimed |
| EP-1438304-B1 | NOVEL SUBSTITUTED 4-PHENYL-4-[1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2006-12-06 | — | — | EP | claimed |
| EP-1438049-B1 | SUBSTITUTED 4-PHENYL-4-(1H-IMIDAZOL-2-YL)-PIPERIDINE DERIVATIVES FOR REDUCING ISCHAEMIC DAMAGE | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-22 | — | — | EP | claimed |
| CN-1283252-C | Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-08 | — | — | CN | claimed |
| CN-1568321-A | Novel substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives and their use as selective non-peptide delta opioid agonists | JANSSEN PHARMACEUTICA NV (BE) | 2005-01-19 | — | — | CN | claimed |
| CN-1568186-A | Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage | JANSSEN PHARMACEUTICA NV (BE) | 2005-01-19 | — | — | CN | claimed |
| US-20050004170-A1 | Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | US | claimed |
| US-20040260096-A1 | Novel substituted 4-phenyl-4-{1h-imidazol-2-yl}-piperidine derivatives and their use as selective non-peptide delta opioid agonists | JANSSEN-CILAG S.A. (ES) | 2004-12-23 | — | — | US | claimed |
| EP-1438049-A2 | SUBSTITUTED 4-PHENYL-4-(1H-IMIDAZOL-2-YL)-PIPERIDINE DERIVATIVES FOR REDUCING ISCHAEMIC DAMAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-21 | — | — | EP | claimed |
| EP-1438304-A1 | NOVEL SUBSTITUTED 4-PHENYL-4- 1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-21 | — | — | EP | claimed |
| WO-2003039440-A2 | SUBSTITUTED 4-PHENYL-4-(1H-IMIDAZOL-2-YL)-PIPERIDINE DERIVATIVES FOR REDUCING ISCHAEMIC DAMAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-15 | — | — | WO | claimed |
| WO-2003033486-A1 | NOVEL SUBSTITUTED 4-PHENYL-4-[1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-24 | — | — | WO | claimed |
| US-7390822-B2 | Substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-7390822-B2 | Substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-7390822-B2 | Substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| EP-1438049-A2 | SUBSTITUTED 4-PHENYL-4-(1H-IMIDAZOL-2-YL)-PIPERIDINE DERIVATIVES FOR REDUCING ISCHAEMIC DAMAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003039440-A2 | SUBSTITUTED 4-PHENYL-4-(1H-IMIDAZOL-2-YL)-PIPERIDINE DERIVATIVES FOR REDUCING ISCHAEMIC DAMAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003033486-A1 | NOVEL SUBSTITUTED 4-PHENYL-4-[1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260096-A1 | Novel substituted 4-phenyl-4-{1h-imidazol-2-yl}-piperidine derivatives and their use as selective non-peptide delta opioid agonists | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRK1 3/4885OPRM1 2/4885 |
| US-20050004170-A1 | Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives for reducing ischaemic damage | NR0B1, NR0B2, ACAD9 | OPRD1 935/4885OPRK1 1252/4885OPRM1 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.